BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20942893)

  • 1. Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?
    Spies PE; Verbeek MM; Olde Rikkert MG; Claassen JA
    J Am Geriatr Soc; 2010 Aug; 58(8):1619-20. PubMed ID: 20942893
    [No Abstract]   [Full Text] [Related]  

  • 2. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
    Zetterberg H; Andreasen N; Blennow K
    Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
    [No Abstract]   [Full Text] [Related]  

  • 6. To tap or not to tap: cerebrospinal fluid biomarkers of Alzheimer's disease.
    Growdon JH
    Ann Neurol; 1998 Jul; 44(1):6-7. PubMed ID: 9667586
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of CSF biomarkers in the diagnostics of memory diseases].
    Remes A; Leikola M; Majamaa K; Nikkanen M; Ruokonen LI; Rusanen M; Tapiola T; Ylikotila P; Vallittu AM; Pirttilä T
    Duodecim; 2009; 125(20):2215-22. PubMed ID: 19998760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
    MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
    Schmand B; Huizenga HM; van Gool WA
    Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New tests for Alzheimer's disease.
    Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
    [No Abstract]   [Full Text] [Related]  

  • 14. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
    Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
    Shoji M
    Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.